Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cidara begins Phase I trial of lead antifungal product candidate CD101 IV
"The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective
"The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective
The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1
This transaction marks the second CodeEvolver licensing agreement between Codexis and a major pharmaceutical company and advances the technology’s business model of multiple sources of revenue. Under the
According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection. The VSV-ZEBOV
Thanks to its innovative formulas, the GelX range alleviates pain in oncological patients, offering different solutions for chemotherapy & radiation induced oral mucositis, xerostomia, dry mouth and radiation
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The
The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 – 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared
The companies will jointly conduct and share the costs of a Phase Ib/II clinical trial seeking to determine whether the combination therapy can improve overall response rate, in
Healthcare providers will now have the option for either a gluteal or deltoid injection site for administering Abilify Maintena to patients with schizophrenia. Abilify Maintena is the first
Allergan’s ANDA product is a generic version of United Therapeutics Corporation’s Tyvaso, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. United